ArticleISRN pharmacology2013
Effects of propofol, a sedative-hypnotic drug, on the lipid profile, antioxidant indices, and cardiovascular marker enzymes in wistar rats.
Article in ISRN pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 21 citations in OpenAlex.
- Propofol inhibits oxidative stress injury through the glycogen synthase kinase 3 beta/nuclear factor erythroid 2-related factor 2/heme oxygenase-1 signaling pathway.Bioengineered · 2022Article
- Building a Network of Adverse Outcome Pathways (AOPs) Incorporating the Tau-Driven AOP Toward Memory Loss (AOP429).Journal of Alzheimer's disease reports · 2022Review
- Propofol protects PC12 cells from cobalt chloride-induced injury by mediating miR-134.Histology and histopathology · 2021Article
- Endothelial-cell inflammation and damage by reactive oxygen species are prevented by propofol via ABCA1-mediated cholesterol efflux.International journal of medical sciences · 2018Article
- Propofol suppresses LPS-induced nuclear accumulation of HIF-1α and tumor aggressiveness in non-small cell lung cancer.Oncology reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the activity of anaesthetic propofol on biological processes has been attracting attention. The effect of propofol on biochemical indices in animals is unknown. In this study, we examined the effects of propofol on lipid profile, antioxidant indices, and cardiovascular marker (CVM) enzymes in rats. The study consists of three groups of seven rats each. Group one received corn oil (Control) while groups two and three received propofol (doses of 2 and 4 mg/kg body weight, resp.). Results showed that administration of propofol caused a significant (P < 0.05) and dose-dependent increase in the levels of total bilirubin. Propofol at 2 and 4 mg/kg increased the levels of serum total cholesterol by 74% and 55%, triglycerides by 97% and 115%, and LDL-C (low-density lipoprotein-cholesterol) by 45% and 73%, respectively, while HDL-C (high-density lipoprotein-cholesterol) decreased by 41% and 54%, respectively. Propofol significantly (P < 0.05) increased the levels of the hepatic reduced glutathione (GSH) and activities of GSH-dependent enzymes. Propofol at 2 and 4 mg/kg increased the activities of CVM enzymes: lactate dehydrogenase by 1.7 and 1.8 folds and creatinine phosphokinase by 2.0 and 2.1 folds, respectively. Taken together, propofol increased the levels of GSH and GSH-dependent enzymes but adversely affected the lipid profile of the rats.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.